Analysts write off Dimension’s lead program after seeing weak data on hemophilia B, shares plunge
Shares of Dimension Therapeutics $DMTX were pummeled on Tuesday, after the biotech posted subpar Factor IX scores on its gene therapy program for hemophilia B.
By the numbers: Patients in one cohort taking DTX101 had peak Factor IX (FIX) expression of 13%, 20% and 12% over 4 to 8 weeks, according to investigators. At the 12-week followup, though, the scores had slipped to 5% and 8% in two patients at 12-weeks follow-up, and 7% for the third patient at 7 weeks. “For the low-dose cohort, expression levels achieved 10-11% peak activity, stabilizing between 3-4% at last follow-up.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.